Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Di Vizio
Correction: Proteomic profiling and functional analysis of extracellular vesicles from metastasis-competent circulating tumor cells in colon cancer - Journal of Experimental & Clinical Cancer Research
Correction: J Exp Clin Cancer Res 44, 102 (2025) https://doi.org/10.1186/s13046-025–03360- 4 Following the publication of the original article [1], the authors identified an error in Figure 2. The current Figure 2 is a duplication of Figure 5. The figure is now being corrected. Incorrect Fig. 2 Cellular component analysis of the EV proteomic cargo based on present-absent analysis.
Proteomic profiling and functional analysis of extracellular vesicles from metastasis-competent circulating tumor cells in colon cancer - Journal of Experimental & Clinical Cancer Research
Abstract Circulating tumor cells (CTCs) are pivotal in cancer progression, and in vitro CTC models are crucial for understanding their biological mechanisms. This study focused on the characterization of extracellular vesicles (EVs) from CTC lines derived from a patient with metastatic colorectal cancer (mCRC) at different stages of progression who progressed despite therapy (thus mirroring the clonal evolution of cancer).
Plasma versus serum for extracellular vesicle (EV) isolation: A duel for reproducibility and accuracy for CNS‐originating EVs biomarker analysis
3 FURTHER CONSIDERATIONS In light of the discussed results above, a few questions remain. The possible contamination of ptEVs in these preparations becomes a serious concern and may confound the results seen and influence the lack of reproducibility that currently exists in the CNS-originating biomarker field.
Targeted therapies for renal cell carcinoma
Abstract The management of patients with metastatic renal cell carcinoma (RCC) has changed dramatically over the past few years. Nephrectomy remains an important intervention for localized RCC but systemic therapy is the mainstay of treatment for patients who relapse after surgery or who have metastatic RCC. Before 2005, medical therapies for RCC were limited to cytokine therapies, which are very toxic and benefit only a small percentage of patients.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Di
Contact Di, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack